{"id":3121,"date":"2026-07-31T12:07:15","date_gmt":"2026-07-31T15:07:15","guid":{"rendered":"https:\/\/naturalmedicalpost.com\/blog\/ralinepag-lowers-pah-clinical-worsening\/"},"modified":"2026-07-31T12:07:15","modified_gmt":"2026-07-31T15:07:15","slug":"ralinepag-lowers-pah-clinical-worsening","status":"publish","type":"post","link":"https:\/\/naturalmedicalpost.com\/blog\/ralinepag-lowers-pah-clinical-worsening\/","title":{"rendered":"Ralinepag Lowers PAH Clinical Worsening Risk in Trial"},"content":{"rendered":"<aside class=\"medical-disclaimer\" style=\"border-left:4px solid #d97706;background:#fef3c7;padding:12px 16px;margin:16px 0;font-size:0.92em;color:#78350f;border-radius:4px\"><strong>&#9888; <\/strong><span>This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.<\/span><\/aside>\n<p>An international phase III clinical trial has shown that oral ralinepag can significantly lower the risk of a first clinical worsening event in patients with pulmonary arterial hypertension, or PAH. These patients were already receiving contemporary background therapy when they entered the study. The main findings were presented earlier this year at the annual meeting of the American Thoracic Society. Following the promising data, United Therapeutics, the manufacturer of ralinepag, submitted a new drug application to the U.S. Food and Drug Administration last month.<\/p>\n<h2>Design of the ADVANCE OUTCOMES Study<\/h2>\n<p>The trial, known as ADVANCE OUTCOMES, enrolled participants over a period from 2019 to 2025. Each individual was randomly assigned to receive either ralinepag or a matching placebo. Those in the ralinepag group started with a dose of 50 micrograms taken once per day. The dose was then gradually increased on a weekly basis through a process called titration. The goal was to reach the highest dose that each person could tolerate without unacceptable side effects. According to the research team led by Humbert, the median doses at week 28 and week 52 were 250 \u00b5g and 300 \u00b5g daily, respectively. After reaching their individual doses, patients were followed for a median duration of 85 weeks in the ralinepag arm and 78.4 weeks in the placebo arm. This careful methodology ensured a robust evaluation of the drug\u2019s effects.<\/p>\n<h2>Defining the Primary Endpoint<\/h2>\n<p>The primary endpoint of the study was the time to the first occurrence of a clinical worsening event. The investigators defined this composite endpoint to include several severe outcomes. Death from any cause was one component of the endpoint. Hospital admission due to worsening PAH or right heart failure was another. The need to start parenteral or inhaled prostacyclin-pathway therapy also counted as an event. Additionally, disease progression and an unsatisfactory long-term clinical response were included. This broad measure was intended to capture the multifaceted nature of PAH deterioration.<\/p>\n<aside aria-label=\"Want to lower blood pressure beyond meds?\" class=\"nbn-cta nbn-cta-high-blood-pressure\" role=\"complementary\">\n<h3 class=\"nbn-cta__headline\">Want to lower blood pressure beyond meds?<\/h3>\n<p class=\"nbn-cta__context\">Heart-friendly strategies with personal follow-up.<\/p>\n<p class=\"nbn-cta__action\"><a class=\"nbn-cta__button\" href=\"https:\/\/backfunnel.com.br\/sfunnel\/16716\/?utm_source=naturalmedical&amp;utm_medium=cta&amp;utm_campaign=high-blood-pressure&amp;utm_content=mid\" rel=\"noopener noreferrer nofollow sponsored\" target=\"_blank\">Chat on WhatsApp<\/a><\/p>\n<\/aside>\n<h2>Efficacy Results: A Significant Reduction<\/h2>\n<p>When the data were analyzed, ralinepag demonstrated a notable reduction in the composite endpoint. The study population consisted of pretreated patients who were classified as low- or intermediate-to-low risk. Most of these individuals were already using two background therapies for PAH. In this group, the event rate was 18% for those on ralinepag, compared to 36% for those on placebo. This difference yielded a hazard ratio of 0.45, indicating a substantial risk reduction. The 95% confidence interval for this hazard ratio ranged from 0.33 to 0.62, underscoring the statistical strength of the finding. Moreover, the treatment effect was consistent across all prespecified subgroups that were examined. These results highlight the potential of ralinepag as a meaningful new option for PAH management.<\/p>\n<h2>Adverse Events and Tolerability<\/h2>\n<p>Despite the clear efficacy benefits, ralinepag was associated with a higher rate of treatment discontinuation prompted by side effects. The most commonly reported adverse events were headache, diarrhea, nausea, and myalgia. These side effects are familiar to physicians who treat PAH, as they are characteristic of drugs acting on the prostacyclin pathway. The safety findings from the trial align with expectations for this class of medications. Monitoring during the study confirmed that tolerability remains a challenge, although the benefits may outweigh these issues for many patients.<\/p>\n<h2>Continuation in an Open-Label Extension<\/h2>\n<p>To provide ongoing therapy, the trial protocol offered an open-label extension study. Patients who completed the main trial as well as those who experienced a clinical worsening event were permitted to enroll. In this extension, all participants receive active ralinepag. This arrangement not only allowed continued access to the drug but also may generate longer-term safety data.<\/p>\n<h2>Regulatory Status and Unanswered Questions<\/h2>\n<p>A noteworthy limitation of ADVANCE OUTCOMES is its use of a placebo comparator. This design choice means that the study cannot determine how ralinepag compares in terms of efficacy or tolerability to other approved prostacyclin-pathway therapies, such as selexipag. Consequently, the exact position of ralinepag in the treatment algorithm for PAH remains unclear. Despite this, the strength of the trial data has already led to a regulatory submission. If the FDA approves ralinepag, it could become a new oral choice for managing this serious condition. As with any medication, patients are advised to discuss the potential benefits and risks with their healthcare provider.<\/p>\n<aside aria-label=\"Want to lower blood pressure beyond meds?\" class=\"nbn-cta nbn-cta-high-blood-pressure\" role=\"complementary\">\n<h3 class=\"nbn-cta__headline\">Want to lower blood pressure beyond meds?<\/h3>\n<p class=\"nbn-cta__context\">Heart-friendly strategies with personal follow-up.<\/p>\n<p class=\"nbn-cta__action\"><a class=\"nbn-cta__button\" href=\"https:\/\/backfunnel.com.br\/sfunnel\/16716\/?utm_source=naturalmedical&amp;utm_medium=cta&amp;utm_campaign=high-blood-pressure&amp;utm_content=end\" rel=\"noopener noreferrer nofollow sponsored\" target=\"_blank\">Chat on WhatsApp<\/a><\/p>\n<\/aside>\n<section class=\"faq-section\">\n<h2>Frequently Asked Questions<\/h2>\n<h3>What was the reduction in clinical worsening events with ralinepag in the ADVANCE OUTCOMES trial?<\/h3>\n<p>Ralinepag reduced the risk of first clinical worsening events by 55% (HR 0.45, 95% CI 0.33-0.62) compared to placebo, with 18% of the ralinepag group experiencing events versus 36% of the placebo group.<\/p>\n<h3>What are the common side effects of ralinepag?<\/h3>\n<p>Common side effects include headache, diarrhea, nausea, and myalgia. Ralinepag was associated with more adverse event-related treatment discontinuations than placebo.<\/p>\n<h3>How does ralinepag compare to selexipag in terms of efficacy?<\/h3>\n<p>Comparative efficacy against selexipag or other prostacyclin-pathway therapies is unknown because the ADVANCE OUTCOMES trial used a placebo comparator.<\/p>\n<\/section>\n<section class=\"newsbot-related-posts\">\n<h2>Read Also<\/h2>\n<ul>\n<li><a href=\"https:\/\/naturalmedicalpost.com\/blog\/beetroot-juice-blood-pressure-lowers\/\"><strong>Beetroot Juice Lowers Blood Pressure Naturally<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/naturalmedicalpost.com\/blog\/beetroot-benefits-nitrates-aid-blood\/\"><strong>Beetroot nitrates aid blood pressure and nutrition<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/naturalmedicalpost.com\/blog\/coffee-safe-heart-aha-much\/\"><strong>How Much Coffee Is Safe for Heart? AHA Issues Statement<\/strong><\/a><\/li>\n<\/ul>\n<\/section>\n<h2>Source<\/h2>\n<ul>\n<li><a href=\"https:\/\/www.medpagetoday.com\/cardiology\/generalcardiology\/122432\" rel=\"nofollow noopener\" target=\"_blank\">www.medpagetoday.com<\/a><\/li>\n<li><a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(26)01011-1\/fulltext\" rel=\"nofollow noopener\" target=\"_blank\">The Lancet<\/a> (www.thelancet.com)<\/li>\n<li><a href=\"https:\/\/disqus.com\/?ref_noscript\" rel=\"nofollow noopener\" target=\"_blank\">comments powered by Disqus.<\/a> (disqus.com)<\/li>\n<\/ul>\n<section class=\"author-box\" style=\"border:1px solid #e5e7eb;background:#f9fafb;padding:16px 20px;margin:24px 0;border-radius:6px;font-size:0.95em;color:#1f2937\">\n<h3 style=\"margin:0 0 8px 0;font-size:1.05em;color:#111827\">About the author<\/h3>\n<p style=\"margin:0 0 6px 0\"><strong>Natural Medical Post Editorial Team<\/strong> &mdash; <em>Health &amp; Wellness Research Team<\/em><\/p>\n<p style=\"margin:0\">Our editorial team reviews health and wellness topics based on peer-reviewed research and trusted medical sources.<\/p>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>A phase III trial found that oral ralinepag significantly lowered the risk of first clinical worsening events in patients with pulmonary arterial hypertension already on background therapy. The results, presented at the American Thoracic Society meeting, showed an 18% event rate versus 36% with placebo, yielding a hazard ratio of 0.45. United Therapeutics has since applied for FDA approval.<\/p>\n","protected":false},"author":1,"featured_media":3123,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_newsbot_seo_title":"Ralinepag Lowers PAH Clinical Worsening Risk in Trial","_newsbot_seo_description":"Ralinepag reduced clinical worsening by over 50% in PAH patients in the ADVANCE OUTCOMES trial, leading to an FDA submission. Side effects included headache and diarrhea.","_newsbot_seo_canonical":"https:\/\/naturalmedicalpost.com\/blog\/ralinepag-lowers-pah-clinical-worsening","_newsbot_seo_og_image":"https:\/\/assets.medpagetoday.net\/media\/images\/122xxx\/122432.jpg","_newsbot_schema_json":"{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"headline\": \"Ralinepag Lowers PAH Clinical Worsening Risk in Trial\", \"description\": \"A phase III trial found that oral ralinepag significantly lowered the risk of first clinical worsening events in patients with pulmonary arterial hypertension already on background therapy. The results, presented at the American Thoracic Society meeting, showed an 18% event rate versus 36% with placebo, yielding a hazard ratio of 0.45. United Therapeutics has since applied for FDA approval.\", \"inLanguage\": \"en\", \"isAccessibleForFree\": true, \"wordCount\": 707, \"author\": {\"@type\": \"Organization\", \"name\": \"Natural Medical Post\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"Natural Medical Post\"}, \"mainEntityOfPage\": \"https:\/\/naturalmedicalpost.com\/blog\", \"datePublished\": \"2026-07-31T15:02:12.587932+00:00\", \"dateModified\": \"2026-07-31T15:02:12.587932+00:00\", \"about\": \"Ralinepag\", \"keywords\": [\"Ralinepag\", \"High Blood Pressure\"], \"image\": {\"@type\": \"ImageObject\", \"url\": \"https:\/\/assets.medpagetoday.net\/media\/images\/122xxx\/122432.jpg\"}, \"speakable\": {\"@type\": \"SpeakableSpecification\", \"cssSelector\": [\".article-lede\", \"h1\", \"meta[name='description']\"]}}, {\"@context\": \"https:\/\/schema.org\", \"@type\": \"BreadcrumbList\", \"itemListElement\": [{\"@type\": \"ListItem\", \"position\": 1, \"name\": \"Natural Medical Post\", \"item\": \"https:\/\/naturalmedicalpost.com\/blog\"}, {\"@type\": \"ListItem\", \"position\": 2, \"name\": \"High Blood Pressure\", \"item\": \"https:\/\/naturalmedicalpost.com\/blog\/high-blood-pressure\"}, {\"@type\": \"ListItem\", \"position\": 3, \"name\": \"Ralinepag Lowers PAH Clinical Worsening Risk in Trial\"}]}, {\"@context\": \"https:\/\/schema.org\", \"@type\": \"FAQPage\", \"mainEntity\": [{\"@type\": \"Question\", \"name\": \"What was the reduction in clinical worsening events with ralinepag in the ADVANCE OUTCOMES trial?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Ralinepag reduced the risk of first clinical worsening events by 55% (HR 0.45, 95% CI 0.33-0.62) compared to placebo, with 18% of the ralinepag group experiencing events versus 36% of the placebo group.\"}}, {\"@type\": \"Question\", \"name\": \"What are the common side effects of ralinepag?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Common side effects include headache, diarrhea, nausea, and myalgia. Ralinepag was associated with more adverse event-related treatment discontinuations than placebo.\"}}, {\"@type\": \"Question\", \"name\": \"How does ralinepag compare to selexipag in terms of efficacy?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Comparative efficacy against selexipag or other prostacyclin-pathway therapies is unknown because the ADVANCE OUTCOMES trial used a placebo comparator.\"}}]}, {\"@context\": \"https:\/\/schema.org\", \"@type\": \"MedicalWebPage\", \"name\": \"Ralinepag Lowers PAH Clinical Worsening Risk in Trial\", \"about\": {\"@type\": \"MedicalCondition\", \"name\": \"High Blood Pressure\"}, \"inLanguage\": \"en\", \"lastReviewed\": \"2026-07-31T15:07:13.968114+00:00\", \"reviewedBy\": {\"@type\": \"Organization\", \"name\": \"Natural Medical Post\"}, \"url\": \"https:\/\/naturalmedicalpost.com\/blog\"}, {\"@context\": \"https:\/\/schema.org\", \"@type\": \"QAPage\", \"mainEntity\": {\"@type\": \"Question\", \"name\": \"What was the reduction in clinical worsening events with ralinepag in the ADVANCE OUTCOMES trial?\", \"answerCount\": 1, \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Ralinepag reduced the risk of first clinical worsening events by 55% (HR 0.45, 95% CI 0.33-0.62) compared to placebo, with 18% of the ralinepag group experiencing events versus 36% of the placebo group.\"}}}, {\"author\": {\"@type\": \"Organization\", \"name\": \"Natural Medical Post Editorial Team\", \"jobTitle\": \"Health &amp; Wellness Research Team\", \"description\": \"Our editorial team reviews health and wellness topics based on peer-reviewed research and trusted medical sources.\"}, \"reviewedBy\": {\"@type\": \"Organization\", \"name\": \"Natural Medical Post Editorial Team\", \"jobTitle\": \"Health &amp; Wellness Research Team\", \"description\": \"Our editorial team reviews health and wellness topics based on peer-reviewed research and trusted medical sources.\"}, \"lastReviewed\": \"2026-07-31T15:07:13.968196+00:00\"}]}","_newsbot_quality_score":"100","_newsbot_quality_grade":"A+","footnotes":""},"categories":[53],"tags":[],"class_list":["post-3121","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-high-blood-pressure"],"views":0,"_links":{"self":[{"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/posts\/3121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/comments?post=3121"}],"version-history":[{"count":1,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/posts\/3121\/revisions"}],"predecessor-version":[{"id":3122,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/posts\/3121\/revisions\/3122"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/media\/3123"}],"wp:attachment":[{"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/media?parent=3121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/categories?post=3121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naturalmedicalpost.com\/blog\/wp-json\/wp\/v2\/tags?post=3121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}